Overview

Breast Cancer - Anti-Progestin Prevention Study 1

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effects of the antiprogestin ulipristal acetate (UA) on the epithelial and stromal compartments of the normal breast in women at increased risk of breast cancer (BC) and to relate these effects to quantitative changes on multiparametric magnetic resonance imaging (MRI). The goal is to define predictive imaging biomarkers for subsequent testing in randomised prevention trials of antiprogestins.
Phase:
Phase 2
Details
Lead Sponsor:
Manchester University NHS Foundation Trust
University Hospital of South Manchester NHS Foundation Trust
Collaborator:
University of Manchester
Treatments:
Progestins
Ulipristal acetate